



Press Release
CADILA PHARMACEUTICALS LIMITED
November 11, 2025
Rating Assigned

Product	Quantum (Rs. Cr)	Long Term Rating	Short Term Rating
Bank Loan Ratings	1680.00	ACUITE A- Stable Assigned	-
Bank Loan Ratings	120.00	-	ACUITE A2+ Assigned
Total Outstanding Quantum (Rs. Cr)	1800.00	-	-
Total Withdrawn Quantum (Rs. Cr)	0.00	-	-

Rating Rationale

Acuite has assigned the long-term rating of '**ACUITE A-**' (read as **ACUITE A minus**) and short term rating of '**ACUITE A2+**' (read as **ACUITE A two plus**) on the Rs. 1800.00 crore bank facilities of Cadila Pharmaceuticals Limited (CPL). The outlook is '**Stable**'.

Rationale for Rating

The rating assigned factors the completion of both greenfield projects in Dahej and Udaipur at CPPL, and the commencement of commercial operations of the same. The rating draws comfort from the significant improvement in Cadila Pharmaceuticals Limited's (CPL - parent company) liquidity position and the expected improvement in CPPL, on account of prepayment of substantial debt portion due over next two years, facilitated through internal accruals and long term finances with elongated maturity. It further takes into account the established presence of the group across the pharmaceutical value chain, with a diversified product portfolio of over 850 products across 300 brands. The group's operations span R&D, APIs, formulations, and marketing, supported by a strong domestic footprint and a global reach extending to over 100 countries. Further, despite reporting stable revenues over the past three years, the group has demonstrated improving operating margins driven by cost optimization. It has also received promoter support in the form of compulsorily convertible debentures and unsecured loans (USLs). These strengths are offset by elevated debt levels resulting from capex spending over the past 3-4 years and weakening debt protection metrics. However, these are expected to improve with the commencement of operations across all plants and capex investments. Furthermore, the group's substantial investments in liquid shares in India and overseas provide additional financial support. The rating also considers regulatory risks across multiple jurisdictions and the impact of shifting international trade policies, which may affect compliance, reputation, and export revenues.

About the Company

Gujarat based, Cadila Pharmaceuticals Limited (CPL) was incorporated in the year 1991. The company is engaged in research, development, and manufacturing of pharmaceutical products across numerous therapeutic areas, including active pharmaceutical ingredients (APIs), finished pharmaceutical formulations, and biotechnology products. The group has its presence in more than 45 therapeutic areas spread across twelve specialties. It caters to cardiovascular, gastrointestinal, analgesics, hematinics, anti-infectives & antibiotics, respiratory agents, antidiabetics and immunological therapeutic segments amongst several

others. Currently, CPL has four manufacturing facilities each located at Ankleshwar, Dholka, Jammu and Addis Abada (Ethiopia) (62.5% JV). The current directors of the company are Mr.

Rajiv Indravadan Modi, Mr. Ramesh Ratilal Choksi, Mr. Abhijat Chandrakant Sheth, Mr. Girdhar Prem Balwani, Mr. Subir Kumar Das, Mr. Rajiv Rajiv Modi, and Mr. Parul Nikunj Shah.

About the Group

CPL and CPL Pharmaceuticals Private Limited (CPPL) are jointly considered as a group for the rating purpose.

CPL Pharmaceuticals Private Limited (CPPL)

Established in 2021, CPPL is a wholly owned subsidiary of Cadila Pharmaceuticals Limited (CPL). The company has developed two greenfield manufacturing facilities - one for API in Dahej, Gujarat, with an installed capacity of 127.13 MTPA, and another for lyophilised injectable formulations in Udaipur, Rajasthan, with an annual capacity of 9.66 million units. CPPL achieved commercial operation date (COD) for the API plant in February 2024, followed by COD for the formulation plant on September 22, 2025. The current directors of the company are Mr. Ramesh Ratilal Choksi, Mr. Amitabha Banerjee, Mr. Rajiv Rajiv Modi, Mr. Biswajit Mitra and Mr. Kamlesh Navaratnalal Shah.

Unsupported Rating

Not Applicable

Analytical Approach

Extent of Consolidation

- Full Consolidation

Rationale for Consolidation or Parent / Group / Govt. Support

To arrive at the rating of CPL Pharmaceuticals Private Limited (CPPL), Acuite has consolidated the financial and business risk profile of CPPL along with its parent Cadila Pharmaceuticals Limited (CPL). The consolidation takes into account the similar line of business, cashflow fungibilities, operational linkages and common management. Acuite also factors in the corporate guarantee extended by CPL for the debt availed by its group entities and investment requirements in other group companies/subsidiaries.

Key Rating Drivers

Strengths

Established presence of the group

CPL is a seven decades old Indian multinational pharmaceutical and one of the largest privately held company based in Ahmedabad, Gujarat. Being an integrated pharmaceutical company, CPL has presence across the entire life sciences value chain i.e. R&D, API, formulations, marketing and development. It has its presence in more than 45 therapeutic areas spread across twelve specialities. Further, it has an international presence in 5 continents in over 100 countries. It also has a strong domestic footprint with nearly 60-65% of revenue derived from domestic market. Further, the manufacturing facilities of CPL are globally accredited by US FDA, PMDA Japan, EDQM Europe, WHO Geneva, Federal Commission for the Protection against Sanitary Risk (COFEPRIS), Therapeutic Goods Administration (TGA) Australia etc. On an overall basis, it has 1400+ formulations registered globally, filed applications for 457 patents globally of which 133 approved, filed applications for 30 Abbreviated New Drug Application (ANDA's) in US against which 16 ANDA's have been approved till date. Further, the group has a strong domestic marketing network with 3000+ field force and cover over 3,00,000+ doctors including all specialists and generalists.

Diversified product profile and focus on innovations

The revenue of group has been diversified across formulations (76.7% of FY25 revenues) & API (23.3%). Further, it is also engaged in undertaking contract manufacturing for generic formulations and APIs. The group has a large portfolio of over 850 products (including brand extension) spread across over 300 brands. Gastroenterology, cardiology, gynecology, diabetology and oncology are some of the key therapeutic segments being catered to. Furthermore, the group has a continued focus on developing innovative products to expand

product portfolio and cater to multiple geographies. The recent API manufacturing capex at Dahej under CPPL features advanced distributed control system (DCS) automation technology and focuses on producing anti-hypertensive (Sartan) APIs. Further, the greenfield formulation plant at Udaipur specializes in producing lyophilized injectable products (which increases product longevity) for various therapeutic areas.

Improving operating margins despite stable scale of operations, expected to grow in the medium term

While the operating revenues of the group have remained stable over the past three years (Rs. 2585.47 Cr. in FY25 (Prov.), Rs. 2529.94 Cr. in FY24, Rs. 2524.9 Cr. in FY23) owing to restructuring of the sales & marketing division and geopolitical disturbances in neighbouring markets of Sri Lanka, Bangladesh, etc, however, the operating margins have improved significantly from 4.85% in FY23 to 8.30% in FY24 and further improved to 10.21% in FY25 (Prov.). The improvement is attributable to multiple factors including input cost reduction, sales cost rationalisation and reduction in the administrative expenses. Going forward, with the commencement of operations of both Dahej (COD – February 2024) & Udaipur (September 2025) unit and completion of new API product – Fluoxetine (expected to start by Dec 2025), the scale of operations is expected to grow at a healthy pace. Further, the recent capex spends on machine replacements, optimization of intermediate costs within API segment and solvent extraction plant is expected to drive growth in margins as well. Moreover, the new plants in CPPL are primarily designed to cater to export markets (approval for Dahej from Europe received in August 2025) which would also contribute to better margins in the medium term.

Strong promoter support & resource mobilisation ability

The group receives strong support from promoters who infused Rs.234 Cr. over FY24 and FY25, in the form of compulsory convertible debentures and unsecured loans, aimed at supporting the ongoing capex at CPPL and aiding the group's debt servicing. Further, in FY26, CPL prepaid substantial debts which resulted in reduction of loan instalment from ~Rs 427 Crore in FY26-FY27 to Rs ~296 Crore for the same period. These prepayments were facilitated through long maturing debt raise of Rs 406 Crore (Rs 211 Crore disbursed till Aug 31, 2025) and also supported by internal accruals. Further, CPPL is in discussion for raising debt of Rs 215 Crore, of which Rs 70-80 Crore to be utilised towards payments of outstanding Udaipur capex and balance shall be utilised towards unlocking of excess promoter margin and prepayment of existing loans thereby reducing obligations from Rs 120.54 Crore in FY26-FY27 to Rs 88.09 Crore for the same period.

Weaknesses

Elevated debt levels owing to capex spends

Over the past 3-4 yrs, the capex spends of the group increased significantly with ~Rs 600 Crore of capex at CPL and ~Rs.741.55 Crore (cost escalated from Rs.485.08 Crore) towards the Udaipur & Dahej project at CPPL. Therefore, this led to a significant elevation in the debt levels of the group from Rs.355.78 Crore in FY22 to Rs.1363.94 Crore in FY25. Further, the delay in COD & cost escalations at CPPL projects caused a stretch in cashflows for repayments. Therefore, the gearing remained high and debt protection metrics remained low over the years, servicing managed through promoter infusions, recovery of loans from group companies, etc. However, the recent debt prepayments at CPL and proposed prepayments at CPPL is expected to ease the debt metrics over the medium term.

Significant investments in and support extended to group companies & associates

CPL has significant investments in its group companies (excluding CPPL) comprising nearly ~47% of its net worth as on March 31, 2025. Of these, primary investments are in Satellite Overseas (Holdings) Ltd which is the investment arm of the Cadila group across the globe. The market value of listed investment as 21.09.2025 is over Rs 1,600 crore. Also, CPL has extended corporate guarantee of Rs.209.11 Crore as on March 31, 2025 (Rs.236.42 Crore as on March 31, 2024) which is primarily towards debt availed by a group company for acquisition of aircraft in 2022. Further, CPL also supports the debt servicing and operations & maintenance of this aircraft as reflected in its high transportation costs. Going forward, any substantial outflows to group companies & associates thereby causing a stretch in company's liquidity shall be a key rating monitorable.

Exposure to regulatory and international trade risks

Indian pharmaceutical companies face regulatory risk from domestic and international compliance requirements. In India, firms follow guidelines set by the Central Drugs Standard Control Organization (CDSCO), while abroad, they undergo inspections and approvals from agencies such as the U.S. FDA and EMA. Lapses like data issues, manufacturing violations, or delayed filings can lead to warning letters, import bans, or product recalls, affecting revenue and reputation. As scrutiny grows, maintaining quality control and transparent operations helps reduce regulatory setbacks.

Additionally, changes in international trade policies—such as the imposition of tariffs or duties on pharmaceutical exports—can impact cost competitiveness and market access, especially in key regulated markets. These tariff barriers may lead to margin pressures and require strategic pricing adjustments to sustain export volumes.

ESG Factors Relevant for Rating

Cadila Group follows Environmental, Social, and Governance (ESG) principles through several operational initiatives. It has introduced a greenhouse gas incentivization program to measure and manage climate impact. The company is building a supply chain focused on environmental and social standards, working closely with suppliers to maintain ethical practices. Cadila invests in technologies and processes that improve product quality and reduce environmental impact, including green chemistry, energy-efficient manufacturing, and waste reduction. On the social front, the company offers insurance benefits and health and safety policies for employees. Its corporate programs support rural development and promote gender equality and diversity. Cadila aims to align its decisions with the interests of patients, society, and the environment, guided by science and purpose.

Rating Sensitivities

- Improvement in scale of operations along with further improvement in operating margins.
- Higher than expected debt levels leading to deterioration in the financial risk profile.
- Stabilisation of operations at the new manufacturing facility
- Any stretch in working capital operations affecting the liquidity

Liquidity Position Adequate

While the debt protection metrics of the group has remained below unity over the past 3-4 years, the debt servicing has been managed through promoter support, recovery from group companies, additional debt raise for reimbursements, etc. However, going forward with the onset of CPPL projects leading to generation of cash accruals and debt prepayments through long maturing debt raise, the debt protection metrics is expected to improve. Moreover, the working capital limits are also moderately utilised at CPL which provides additional liquidity cushion. Further, as articulated by the management, the dilution of investments of CPL in some of the listed entities can also provide liquidity buffers if required.

Outlook : Stable

Other Factors affecting Rating

None

Key Financials

Particulars	Unit	FY 25 (Provisional)	FY 24 (Actual)
Operating Income	Rs. Cr.	2585.47	2529.94
PAT	Rs. Cr.	19.70	66.40
PAT Margin	(%)	0.76	2.62
Total Debt/Tangible Net Worth	Times	1.45	1.37
PBDIT/Interest	Times	1.71	2.47

Status of non-cooperation with previous CRA (if applicable)

None

Any Other Information

None

Applicable Criteria

- Application Of Financial Ratios And Adjustments: <https://www.acuite.in/view-rating-criteria-53.htm>
- Consolidation Of Companies: <https://www.acuite.in/view-rating-criteria-60.htm>
- Default Recognition: <https://www.acuite.in/view-rating-criteria-52.htm>
- Manufacturing Entities: <https://www.acuite.in/view-rating-criteria-59.htm>

Note on complexity levels of the rated instrument

In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite's categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria "Complexity Level Of Financial Instruments" on www.acuite.in.

Rating History :

Not Applicable

Annexure - Details of instruments rated

Lender's Name	ISIN	Facilities	Date Of Issuance	Coupon Rate	Maturity Date	Quantum (Rs. Cr.)	Complexity Level	Rating
Not Applicable	Not avl. / Not appl.	Proposed Secured Working Capital Bank Facility	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	120.00	Simple	ACUITE A2+ Assigned
Not Applicable	Not avl. / Not appl.	Proposed Secured Working Capital Bank Facility	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	440.00	Simple	ACUITE A- Stable Assigned
Not Applicable	Not avl. / Not appl.	Proposed Unsecured Working Capital Bank Facility	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	113.82	Simple	ACUITE A- Stable Assigned
Bank Of Baroda	Not avl. / Not appl.	Term Loan	16 Jan 2023	Not avl. / Not appl.	28 Feb 2033	278.13	Simple	ACUITE A- Stable Assigned
BANK OF INDIA (BOI)	Not avl. / Not appl.	Term Loan	23 Jun 2021	Not avl. / Not appl.	30 Mar 2030	57.05	Simple	ACUITE A- Stable Assigned
BANK OF INDIA (BOI)	Not avl. / Not appl.	Term Loan	17 May 2023	Not avl. / Not appl.	30 Jun 2030	85.00	Simple	ACUITE A- Stable Assigned
Canara Bank	Not avl. / Not appl.	Term Loan	16 Sep 2023	Not avl. / Not appl.	30 Sep 2028	240.00	Simple	ACUITE A- Stable Assigned
Aditya Birla Finance Limited	Not avl. / Not appl.	Term Loan	07 Mar 2025	Not avl. / Not appl.	31 Mar 2035	100.00	Simple	ACUITE A- Stable Assigned
Bajaj Finance Ltd.	Not avl. / Not appl.	Term Loan	24 May 2025	Not avl. / Not appl.	07 Jun 2031	50.00	Simple	ACUITE A- Stable Assigned
BANK OF MAHARASHTRA	Not avl. / Not appl.	Term Loan	02 Jun 2025	Not avl. / Not appl.	30 Jun 2035	106.00	Simple	ACUITE A- Stable Assigned
Indian Bank	Not avl. / Not appl.	Term Loan	15 Jul 2025	Not avl. / Not appl.	30 Jun 2035	150.00	Simple	ACUITE A- Stable Assigned
RBL Bank	Not avl. / Not appl.	Term Loan	09 Aug 2024	Not avl. / Not appl.	27 Sep 2030	60.00	Simple	ACUITE A- Stable Assigned

***Annexure 2 - List of Entities (applicable for Consolidation or Parent / Group / Govt. Support)**

Sr. No.	Entities
---------	----------

1	Cadila Pharmaceuticals Limited - CPL
2	CPL Pharmaceuticals Private Limited - CPPL

Contacts

Mohit Jain Chief Analytical Officer-Rating Operations	Contact details exclusively for investors and lenders
Parth Patel Senior Analyst-Rating Operations	Mob: +91 8591310146 Email ID: analyticalsupport@acuite.in

About Acuité Ratings & Research

Acuité is a full-service Credit Rating Agency registered with the Securities & Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI) for Bank Loan Ratings under BASEL-II norms in the year 2012. Acuité has assigned ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Kanjurmarg, Mumbai.

Disclaimer: An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Ratings assigned by Acuité are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind, arising from the use of its ratings. Ratings assigned by Acuité are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.acuite.in) for the latest information on any instrument rated by Acuité. Please visit <https://www.acuite.in/faqs.htm> to refer FAQs on Credit Rating.

Note: None of the Directors on the Board of Acuité Ratings & Research Limited are members of any rating committee and therefore do not participate in discussions regarding the rating of any entity.